MOTIVATION LETTER The Qatar Development Bank Pre-Accelerator Program 2026 targets early-stage startups with a validated MVP and a clear path to market. My venture, an AI-driven B2B SaaS platform for drug discovery, fits that description precisely. The platform predicts drug resistance mutations from protein sequence alone, without requiring crystal structures, and has achieved an AUROC of 0.804 on the Platinum benchmark, outperforming the published state of the art at 0.70. This is a working proof-of-concept with published benchmark results, not a concept. The venture addresses a bottleneck that costs pharmaceutical companies billions annually. Most resistance prediction tools require crystal structures, which exist for only about 18 percent of clinically relevant proteins. My platform covers 100 percent of mutations because it works from sequence data alone. That coverage gap is the commercial wedge. Servier in Suresnes has agreed to a pilot, which will convert the technical validation into revenue. The roadmap is specific: fine-tune the ESM-2 protein language model on the SKEMPI 3K mutation dataset, reach an AUROC of at least 0.70 on that benchmark, then deliver the Servier pilot and establish annual recurring revenue. The program's selection criteria emphasize B2B SaaS, AI, and startups preparing to raise investment. My venture is all three. The platform is a subscription-based SaaS tool for biopharma R&D teams, built on a proprietary machine learning pipeline that combines ESM-2 delta-embeddings with ECFP4 drug fingerprints and a Random Forest classifier. The target customers are computational biology and drug discovery teams at mid-size and large pharma companies. The program's international scope, accepting startups from Africa, Europe, and the Middle East, accommodates a Nigeria-based founder with European pharma partnerships already in place. The program's structure, with online sessions and in-person engagement in Doha from October 5 to November 25, 2026, offers the mentorship and market-readiness support my venture needs at this stage. I am preparing to raise a pre-seed round, and the program's pitch preparation and investor network would directly support that effort. The potential for up to 75,000 USD in exchange for 6 percent equity is a viable pre-seed instrument for a venture at this stage. The venture is not yet incorporated, which I understand is a consideration for the program. I am prepared to incorporate in a suitable jurisdiction before the program start date if selected. The technical validation is complete; the commercial validation is underway. This program is the right next step. RESEARCH STATEMENT The venture's core technology is a machine learning pipeline that predicts drug resistance mutations from protein sequence alone. The system uses ESM-2 protein language model delta-embeddings to represent the structural and functional context of each mutation, combines these with ECFP4 drug fingerprints to represent the drug compound, and feeds both into a Random Forest classifier. The output is a probability score indicating whether a given mutation confers resistance to a given drug. The technical validation is rigorous. On the Platinum benchmark, a set of 553 mutations with protein-grouped cross-validation, the model achieves an AUROC of 0.804 with a standard deviation of 0.025. This exceeds the published state of the art, mCSM-lig, which achieves approximately 0.70 on the same benchmark. On SKEMPI 2.0, a binding affinity benchmark, the model achieves an AUROC of 0.634. The critical advantage is coverage: structure-based tools can only analyze proteins with known crystal structures, which covers roughly 18 percent of clinically relevant mutations. My sequence-based approach covers 100 percent of mutations. The next technical milestone is fine-tuning the ESM-2 model on the SKEMPI 3K mutation dataset. This dataset contains approximately 3,000 binding affinity mutations and will improve the model's generalization across protein families. The target is an AUROC of at least 0.70 on this dataset. This milestone is scheduled for completion before the Servier pilot begins. The commercial application is a B2B SaaS platform for pharmaceutical R&D teams. Drug resistance is a critical failure mode in oncology, antiviral therapy, and antimicrobial drug development. A computational tool that predicts resistance mutations early in the drug development pipeline allows teams to design drugs that are less susceptible to resistance, or to anticipate resistance pathways before they emerge in clinical trials. The platform is designed to integrate into existing computational biology workflows, providing predictions for specific drug-mutation pairs on demand. The business model is subscription-based, with tiered pricing based on usage volume and API access. The target customer is the computational biology or cheminformatics team at a mid-size or large pharmaceutical company. The Servier pilot, scheduled at their Suresnes facility, will validate the platform in a real industrial setting and provide the first reference customer. Paris-Saclay (I2BC) and the Institut Pasteur are named research partners who will contribute to validation studies and provide scientific credibility. The venture is at pre-seed stage. The proof-of-concept is validated with published benchmark results. The company is not yet incorporated. The immediate priorities are incorporation, completion of the SKEMPI 3K fine-tuning milestone, and execution of the Servier pilot. The funding sought from this program would support compute costs for the fine-tuning work, legal and incorporation fees, and the founder's runway during the pilot period. The global applicability of the platform is a strategic advantage. Drug resistance is a universal problem in pharmaceutical development, and the platform's sequence-based approach removes the structural data bottleneck that limits competing tools. The MENA region, with its growing investment in healthcare and biotechnology, represents a potential market for pharma AI tools, and the Qatar Development Bank's network could open regional partnerships. ESSAY RESPONSE: MARKET VALIDATION AND TRACTION The venture has two forms of validation: technical and commercial. Technical validation is the published benchmark performance. The model achieves an AUROC of 0.804 on the Platinum benchmark, outperforming the published state of the art at 0.70. It covers 100 percent of mutations versus approximately 18 percent for structure-limited tools. These numbers are verifiable and reproducible. Commercial validation is in progress. Servier, a major European pharmaceutical company, has agreed to a pilot at their Suresnes facility. This pilot will test the platform on real drug development use cases and establish the foundation for a paid subscription. The pilot is the first step toward annual recurring revenue. Paris-Saclay (I2BC) and the Institut Pasteur are named research partners, providing scientific validation and access to domain expertise. Sanofi in Gentilly is a named partner for potential future collaboration. The venture is currently preparing to raise a pre-seed round. The program's focus on startups that are raising or preparing to raise investment aligns with this stage. The 75,000 USD investment in exchange for 6 percent equity, if offered, would serve as the initial pre-seed capital, funding incorporation, compute costs, and the founder's runway through the Servier pilot. The market need is clear. Drug resistance is a multi-billion dollar problem in oncology, antivirals, and antimicrobial development. Existing tools are limited by structural data requirements. The platform addresses this gap with a sequence-based approach that is faster, cheaper, and more thorough. The B2B SaaS model targets pharmaceutical R&D teams who need resistance predictions integrated into their existing workflows. ESSAY RESPONSE: COMMITMENT AND PROGRAM FIT The program schedule, running from October 5 to November 25, 2026, with online sessions and in-person engagement in Doha, fits my current stage. The venture is pre-incorporation, which means I have flexibility to dedicate time to the program. The mentorship and market-readiness support are the primary value I seek, alongside the potential investment and the network of the Qatar Development Bank. The program's target sectors include B2B SaaS and AI, which are the venture's core categories. The international scope, accepting startups from Africa, Asia, Europe, and the Middle East, accommodates my Nigeria-based operations and European pharma partnerships. The program's emphasis on startups that can benefit from mentorship and market-readiness support matches my current needs: incorporation strategy, pricing and packaging for the SaaS product, and pitch preparation for the pre-seed round. I am committed to the full program schedule, including travel to Doha for in-person sessions. The venture is at a stage where structured support can accelerate the path to the Servier pilot and the pre-seed raise. The program's investor network and pitch preparation would directly support the fundraising goal. CHECKLIST - [ ] Verify current program deadline and application portal on Qatar Development Bank website - [ ] Confirm incorporation requirement and timeline; prepare to incorporate before program start if required - [ ] Prepare pitch deck with benchmark results (AUROC 0.804 Platinum, 0.634 SKEMPI 2.0) and coverage advantage (100 percent vs 18 percent) - [ ] Obtain letter of intent or confirmation from Servier for the pilot - [ ] Prepare financial model showing path to annual recurring revenue from Servier pilot - [ ] Confirm equity terms (75,000 USD for 6 percent) and assess fit with pre-seed fundraising plan - [ ] Prepare CV and founder background summary (pharmacist, ML engineer, sole author) - [ ] Prepare technical appendix with methodology details (ESM-2 delta-embeddings, ECFP4, Random Forest) - [ ] Confirm travel and accommodation plans for in-person sessions in Doha, October 5 to November 25, 2026 - [ ] Verify eligibility for Qatar-based programs as a Nigeria-based founder EDITOR NOTES - Eligibility risk: The program may require incorporation before application or program start. The venture is not yet incorporated. Confirm this requirement early and prepare to incorporate in a suitable jurisdiction if needed. - The Servier pilot is named in the profile but not confirmed in writing. Obtain a letter of intent or email confirmation before submission to substantiate the commercial traction claim. - The program's MENA geographic focus is a moderate fit for a Nigeria-based founder. The application should emphasize the international scope of the program and the venture's global applicability to mitigate this. - The equity terms (75,000 USD for 6 percent) imply a 1.25M USD valuation. Assess whether this aligns with the pre-seed fundraising strategy or if it would complicate future rounds. - The SKEMPI 3K fine-tuning milestone is scheduled but not yet completed. Do not claim results on this dataset; describe it as a planned milestone with a target AUROC of at least 0.70.